abstract
- Quantitative assessment of risks for cardiometabolic diseases (CMDs) is essential for preventive healthcare and early diagnosis of serious conditions like cardiovascular diseases and metabolic disorders. Detecting a panel of clinically tested CMD biomarkers presents a multi-facet approach that can significantly reduce CMD risks and associated healthcare burden.